Latest Administration News

Regis Healthcare delivered a robust FY25 performance with a 14.5% revenue increase and a dramatic turnaround to a $49 million net profit. The company is advancing growth through acquisitions and greenfield developments, positioning itself strongly ahead of upcoming sector reforms.

Praemium Limited reported a robust 25% revenue increase and a 55% jump in net profit for FY2025, driven by strategic client wins and innovative product launches.

Praemium Limited reported robust FY25 results with revenue climbing 24.6% to $103 million and net profit after tax soaring 55% to $13.56 million, underpinned by strong growth in funds under administration and strategic product launches.

Alfabs Australia Limited reported a robust 242% increase in net profit for FY2025 despite a slight dip in revenue, underpinned by strong operational performance and major contract deliveries. The company declared a final dividend, signaling confidence in its financial position.

Ansell Limited has announced an unfranked ordinary dividend of USD 0.28 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan available to select shareholders.

Plato Income Maximiser Limited has reported a robust financial year ending June 2025, with net profit after tax rising to $83.6 million and its investment portfolio outperforming the benchmark in both income and total return. The company also maintained its highest-ever fully franked monthly dividends since listing.

Health and Plant Protein Group Limited (HPP) reported a reduced net loss of $528,000 for FY2025, following the receipt of final proceeds from its US divestment. The Board signals plans to return capital and pursue new corporate opportunities.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

Cannindah Resources announces the resignation of Managing Director Tom Pickett and appoints Cam Switzer as Interim CEO, signaling a new phase for the Mt Cannindah copper and gold project.

The ASX has suspended the securities of 36 companies for failing to pay their annual listing fees by the August 21 deadline, with a looming delisting threat if fees remain unpaid by August 28.

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.

Inghams Group reported a stable underlying EBITDA of $236.4 million for FY25 despite softer market conditions and customer changes, while guiding for a modest earnings dip in FY26 as cost reduction programs take effect.